FGF23 and hypophosphatemia: The most common adverse effect of iron carboxymaltose is hypophosphatemia, which is caused by an increase in urinary phosphate excretion from the upregulation of the phosphaturic hormone fibroblast growth factor 23 (FGF23) [16].